Natural Antibiotic Amicoumacin Analogue, API

COOPERATION OPTIONS

LICENSE

FROM 100 MILLION RUR

RESEARCH PARTNERSHIP

FROM 25 MILLION RUR

more detail

ABOUT THE PROJECT

Natural Antibiotic Amicoumacin Analogue, API

AN UNIQUE METHODOLOGY FOR NEW ANTIBIOTICS DEVELOPMENT AND SYNTHESIS

An original method of chemical synthesis of natural antibiotic Amicoumacin, which has high efficiency against antibiotic-resistant bacteria, was developed, using the technology of microfluidic screening*. To date, the first stable analogue of Amicoumacin has been obtained. Thirteen bacterial strains were tested to identify the most active analogue of Amicoumacin, for six of them the value of the minimum inhibitory concentration of less than 10 µg/ml was shown.

*Unique technology for microfluidic screening of antibiotic activity at the single cell level offers exciting opportunities for the discovery of new effective antibiotics. It combines high-throughput screening, large-scale sequencing and genomic mining and allows the use of non-classical sources of antibacterial drugs (human and animal physiological fluids microbiota, soil microbiota, sources under extreme conditions), searching for specific antimicrobial drugs for a given pathogen. 

STAGE OF DEVELOPMENT

Natural Antibiotic Amicoumacin Analogue, API

COOPERATION OPTIONS

LICENSE

FROM 100 MILLION RUR

RESEARCH PARTNERSHIP

FROM 25 MILLION RUR

more detail

ABOUT THE PROJECT

Natural Antibiotic Amicoumacin Analogue, API

AN UNIQUE METHODOLOGY FOR NEW ANTIBIOTICS DEVELOPMENT AND SYNTHESIS

An original method of chemical synthesis of natural antibiotic Amicoumacin, which has high efficiency against antibiotic-resistant bacteria, was developed, using the technology of microfluidic screening*. To date, the first stable analogue of Amicoumacin has been obtained. Thirteen bacterial strains were tested to identify the most active analogue of Amicoumacin, for six of them the value of the minimum inhibitory concentration of less than 10 µg/ml was shown.

*Unique technology for microfluidic screening of antibiotic activity at the single cell level offers exciting opportunities for the discovery of new effective antibiotics. It combines high-throughput screening, large-scale sequencing and genomic mining and allows the use of non-classical sources of antibacterial drugs (human and animal physiological fluids microbiota, soil microbiota, sources under extreme conditions), searching for specific antimicrobial drugs for a given pathogen. 

STAGE OF DEVELOPMENT

STAGE OF DEVELOPMENT
& RESULTS OF INTELLECTUAL ACTIVITY STATUS


APPLICATION

Creation of new highly effective and safe drugs with antibacterial action for the treatment of hospital-acquired multidrug-resistant infections.

BENEFITS

The mechanism of action of Amicoumacin A is based on specific ribosome inhibition, the antibiotic acts on both prokaryotic and eukaryotic ribosomes

Effective against Helicobacter pilory, the agent that causes stomach ulcers
EFFECTIVE AGAINST MRSA STRAINS
ANTITUMOR ACTIVITY AND ANTIVIRAL ACTIVITY 

COOPERATION OPTIONS

Options for project implementation include Intellectual Property license agreement and/or further product development together with investor.
license agreement 

Conclusion of agreements on disposal of exclusive intellectual property rights (license agreements). 

Approximate investment amount: 

• Granting the right to use results of intellectual activity - starting at RUB 100 million RUR

• Royalty 5%

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to bring research to the market launching stage and to organize product manufacturing and sales.

Approximate investment amount: 

Starting at 385 million RUR 

Small Innovation Enterprise (SIE)

Creation of the project company as a Small Innovation Enterprise (SIE), the founders of which include IBCh RAS and some investor & scientists-developers.

The aim: to reach the further research stage(s) and to sale of the scientific product in the form of sublicensing.

Approximate investment amount:

• Preclinical studies
Starting at 25 million RUR

• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 150 million RUR

investment partnership agreements

Conclusion of investment partnership agreements for further research stages on the investor basis with the participation of IBCh RAS.

The aim: to obtain a scientific product or "ready to market" product.

Approximate investment amount: 

• Preclinical studies
Starting at 25 million RUR

• Clinical trials, phase 1
Starting at 50 million RUR

• Clinical trials, phase 2
Starting at 100 million RUR

• Clinical trials, phase 3
Starting at 150 million RUR

• Start manufacturing
Starting at 10 million RUR

• Promotion activities
Starting at 50 million RUR

DEVELOPERS

The Shemyakin & Ovchinnikov Institute of bioorganic chemistry (IBCh) of the Russian Academy of Sciences is one of the largest Russian scientific organizations. The Institute is a leader in fundamental and innovative researches on the fields of molecular, structural and cell biology, bioorganic chemistry, biophysics, bioengineering, cell technologies, “in vivo” molecular based bioimaging, genome editing, bioinformatics etc. This multidisciplinary structure allows large-scale research at the interface of sciences, where the most interesting scientific discoveries are born today.

The hallmark of the IBCh RAS is the concentration of efforts and resources on solving the most urgent and complicated problems on the field of life sciences. Talented young people and leading specialists, including Russian and foreign science leaders, Nobel Prize laureates and members of the international advisory council of the Institute are involved in.

HEAD OF THE PROJECT

IVAN SMIRNOV

Dr. of Sc. in Chemistry

Deputy Director of IBH RAS

Head of the Laboratory of High-Performance Screening of Biological Objects

 


PUBLICATIONS

A kinase bioscavenger provides antibiotic resistance by extremely tight substrate binding.

Terekhov SS, Mokrushina YA, Nazarov AS, Zlobin A, Zalevsky A, Bourenkov G, Golovin A, Belogurov A Jr, Osterman IA, Kulikova AA, Mitkevich VA, Lou HJ, Turk BE, Wilmanns M, Smirnov IV, Altman S, Gabibov AG.

Sci Adv. 2020 Jun 24;6(26):eaaz9861. doi: 10.1126/sciadv.aaz9861. PMID: 32637600; PMCID: PMC7314540.

Deep Functional Profiling Facilitates the Evaluation of the Antibacterial Potential of the Antibiotic Amicoumacin.

Terekhov SS, Nazarov AS, Mokrushina YA, Baranova MN, Potapova NA, Malakhova MV, Ilina EN, Smirnov IV, Gabibov AG.

Antibiotics. 2020 Apr 2;9(4):157. doi: 10.3390/antibiotics9040157. PMID: 32252356; PMCID: PMC7235827.

Ultrahigh-throughput functional profiling of microbiota communities.

Terekhov SS, Smirnov IV, Malakhova MV, Samoilov AE, Manolov AI, Nazarov AS, Danilov DV, Dubiley SA, Osterman IA, Rubtsova MP, Kostryukova ES, Ziganshin RH, Kornienko MA, Vanyushkina AA, Bukato ON, Ilina EN, Vlasov VV, Severinov KV, Gabibov AG, Altman S.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9551-9556. doi: 10.1073/pnas.1811250115. Epub 2018 Sep 4. PMID: 30181282; PMCID: PMC6156654.

The Russian Federation will create an antibiotic against Staphylococcus aureus based on the bacteria of the skin beetle

CONTACT us

get in touch

On cooperation issues please contact the head of NTI Center project department
Sergey Semenov
E-mail consortium@cnti-ibch.ru
address 16/10, Miklukho-Maklaya St, Moscow, Russian Federation, 117997
All products and services of NTI Center IBHh RAS
view more